Purple Biotech Ltd
PPBT0.706USD
-0.009-1.22%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
6.38MMarket Cap
LossP/E TTM
More Details of Purple Biotech Ltd Company
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
Purple Biotech Ltd Info
Ticker SymbolPPBT
Company namePurple Biotech Ltd
IPO dateSep 03, 1978
CEOEfron (Gil)
Number of employees9
Security typeDepository Receipt
Fiscal year-endSep 03
Address4 Oppenheimer St.
CityREHOVOT
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIsrael
Postal code7670104
Phone97239333121
Websitehttps://purple-biotech.com/
Ticker SymbolPPBT
IPO dateSep 03, 1978
CEOEfron (Gil)
Company Executives of Purple Biotech Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Steven Steinberg
Mr. Steven Steinberg
Independent Director
Independent Director
--
--
Mr. Avraham Ben-Tzvi
Mr. Avraham Ben-Tzvi
General Counsel, Secretary
General Counsel, Secretary
--
--
Mr. Yisrael Gewirtz
Mr. Yisrael Gewirtz
Internal Auditor
Internal Auditor
--
--
Dr. Eric K. Rowinsky, M.D.
Dr. Eric K. Rowinsky, M.D.
Chairman of the Board
Chairman of the Board
--
--
Mr. Gil Efron, CPA
Mr. Gil Efron, CPA
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Itzhak Israel
Mr. Itzhak Israel
Director
Director
--
--
Dr. Bertrand Liang
Dr. Bertrand Liang
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Arie Weber
Mr. Arie Weber
Independent Director
Independent Director
--
--
Ms. Revital Stern-Raff
Ms. Revital Stern-Raff
Independent Director
Independent Director
--
--
Dr. Hadas Reuveni
Dr. Hadas Reuveni
Founder and Chief Technology Officer of TyrNovo (a subsidiary)
Founder and Chief Technology Officer of TyrNovo (a subsidiary)
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Steven Steinberg
Mr. Steven Steinberg
Independent Director
Independent Director
--
--
Mr. Avraham Ben-Tzvi
Mr. Avraham Ben-Tzvi
General Counsel, Secretary
General Counsel, Secretary
--
--
Mr. Yisrael Gewirtz
Mr. Yisrael Gewirtz
Internal Auditor
Internal Auditor
--
--
Dr. Eric K. Rowinsky, M.D.
Dr. Eric K. Rowinsky, M.D.
Chairman of the Board
Chairman of the Board
--
--
Mr. Gil Efron, CPA
Mr. Gil Efron, CPA
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Itzhak Israel
Mr. Itzhak Israel
Director
Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Nov 20
Updated: Thu, Nov 20
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Lincoln Alternative Strategies LLC
6.51%
Orca Capital GmbH
3.30%
Virtu Americas LLC
0.53%
Citadel Advisors LLC
0.44%
GAMMA Investing LLC
0.14%
Other
89.08%
Shareholders
Shareholders
Proportion
Lincoln Alternative Strategies LLC
6.51%
Orca Capital GmbH
3.30%
Virtu Americas LLC
0.53%
Citadel Advisors LLC
0.44%
GAMMA Investing LLC
0.14%
Other
89.08%
Shareholder Types
Shareholders
Proportion
Corporation
6.51%
Investment Advisor
3.38%
Research Firm
0.77%
Hedge Fund
0.44%
Investment Advisor/Hedge Fund
0.14%
Other
88.76%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
40
355.08K
3.82%
+98.77K
2025Q2
37
55.19K
1.82%
-201.60K
2025Q1
39
103.31K
6.70%
-153.87K
2024Q4
41
133.07K
5.02%
-58.34K
2024Q3
39
222.98K
11.78%
+111.64K
2024Q2
39
147.98K
8.71%
+1.90K
2024Q1
40
184.47K
11.90%
+40.99K
2023Q4
40
174.27K
11.63%
+106.33K
2023Q3
38
64.91K
3.14%
-5.47K
2023Q2
37
13.88K
1.30%
-49.49K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Lincoln Alternative Strategies LLC
605.00K
6.7%
+605.00K
--
Sep 04, 2025
Orca Capital GmbH
306.39K
3.39%
+306.39K
--
Sep 07, 2025
GAMMA Investing LLC
12.65K
0.14%
+8.22K
+185.64%
Sep 30, 2025
BNP Paribas Securities Corp. North America
6.28K
0.07%
+900.00
+16.74%
Jun 30, 2025
Morgan Stanley & Co. LLC
4.57K
0.05%
+100.00
+2.24%
Jun 30, 2025
UBS Financial Services, Inc.
23.14K
0.26%
+119.00
+0.52%
Jun 30, 2025
Rhumbline Advisers Ltd. Partnership
1.08K
0.01%
+275.00
+34.16%
Jun 30, 2025
Simplex Trading, LLC
53.00
0%
+53.00
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Sep 06, 2024
Merger
20→1
Sep 06, 2024
Merger
20→1
Sep 06, 2024
Merger
20→1
Sep 06, 2024
Merger
20→1
Aug 13, 2020
Merger
10→1
Aug 13, 2020
Merger
10→1
Date
Type
Ratio
Sep 06, 2024
Merger
20→1
Sep 06, 2024
Merger
20→1
Sep 06, 2024
Merger
20→1
Sep 06, 2024
Merger
20→1
Aug 13, 2020
Merger
10→1
Aug 13, 2020
Merger
10→1
Aug 13, 2020
Merger
10→1
Aug 13, 2020
Merger
10→1
FAQs
Who are the top five shareholders of Purple Biotech Ltd?
The top five shareholders of Purple Biotech Ltd are:
Lincoln Alternative Strategies LLC holds 605.00K shares, accounting for 6.70% of the total shares.
Orca Capital GmbH holds 306.39K shares, accounting for 3.39% of the total shares.
GAMMA Investing LLC holds 12.65K shares, accounting for 0.14% of the total shares.
BNP Paribas Securities Corp. North America holds 6.28K shares, accounting for 0.07% of the total shares.
Morgan Stanley & Co. LLC holds 4.57K shares, accounting for 0.05% of the total shares.
Lincoln Alternative Strategies LLC holds 605.00K shares, accounting for 6.70% of the total shares.
Orca Capital GmbH holds 306.39K shares, accounting for 3.39% of the total shares.
GAMMA Investing LLC holds 12.65K shares, accounting for 0.14% of the total shares.
BNP Paribas Securities Corp. North America holds 6.28K shares, accounting for 0.07% of the total shares.
Morgan Stanley & Co. LLC holds 4.57K shares, accounting for 0.05% of the total shares.
What are the top three shareholder types of Purple Biotech Ltd?
The top three shareholder types of Purple Biotech Ltd are:
Lincoln Alternative Strategies LLC
Orca Capital GmbH
Virtu Americas LLC
Lincoln Alternative Strategies LLC
Orca Capital GmbH
Virtu Americas LLC
How many institutions hold shares of Purple Biotech Ltd (PPBT)?
As of 2025Q3, 40 institutions hold shares of Purple Biotech Ltd, with a combined market value of approximately 355.08K, accounting for 3.82% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 2.00%.
What is the biggest source of revenue for Purple Biotech Ltd?
In --, the -- business generated the highest revenue for Purple Biotech Ltd, amounting to -- and accounting for --% of total revenue.
